<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-157430</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Is obesity in psoriatic arthritis associated with a poorer therapeutic response and more adverse effects of treatment with an anchor drug?</dc:title>
<dc:description xml:lang="en">Objectives. To assess the association between obesity, control of inflammatory activity and increased adverse effects in psoriatic arthritis (PsA) with disease-modifying anti-inflammatory drugs (DMARD). Methods. A systematic literature review was performed using MEDLINE and EMBASE databases following the guidelines of the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) consensus statement. Studies were selected if they included patients with PsA, obesity was studied as a predictive factor, and the outcome was adverse effects, including efficacy failure. Quality was assessed using an ad hoc risk of bias tool. A qualitative analysis was carried out by type of study and study population, quality and specific results. Results. We found 1043 articles, discarding most of them on the basis of title and abstract. Ten articles were studied in detail and finally excluded three. The majority concluded, with statistically significant results, that in patients with PsA and treated with TNF&amp;#945; inhibitors (TNF&amp;#945;i), obesity is associated with poorer chances of achieving and maintaining a minimal disease activity, higher treatment discontinuation rates, and lower skin response. Regarding conventional synthetic DMARD, a trend toward a moderate increase in transaminases with methotrexate (MTX) was observed in obese patients with PsA. Conclusions. Obesity is a negative predictor of clinical response in patients with PsA being treated with TNF&amp;#945;i. Except MTX hepatotoxicity, no other adverse effects, either with TNF&amp;#945;i or other drugs, were found in relation to obesity in PsA (AU)</dc:description>
<dc:creator>Galíndez, Eva</dc:creator>
<dc:creator>Carmona, Loreto</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos. Estudiar si en la artritis psoriásica (APs) hay asociación entre la obesidad, el control de la actividad inflamatoria y el aumento de efectos adversos con los fármacos modificadores de la enfermedad (FAME). Métodos. Revisión sistemática de la literatura utilizando las bases de datos Medline y Embase según las guías del consenso MOOSE. Se incluyeron estudios en pacientes con APs, en los que la obesidad fuera factor predictor de efectos adversos y el desenlace fuera toxicidad, incluido fallo de eficacia. La calidad se evaluó mediante una escala de riesgo de sesgos ad hoc. Se realizó un análisis cualitativo por tipo de estudio y población estudiada, calidad y resultados específicos. Resultados. Se encontraron 1.043 artículos, la mayoría se descartaron por título y abstract. Se estudiaron en detalle 10, excluyéndose finalmente 3. La mayoría concluye con resultados estadísticamente significativos que la obesidad en pacientes con APs e inhibidores del TNF-&amp;#945; (iTNF-&amp;#945;) se asocia a una probabilidad menor de alcanzar y mantener la mínima actividad inflamatoria, con mayor tasa de interrupción del tratamiento y menor tasa de respuesta cutánea. En relación con los FAME sintéticos convencionales, se observó en obesos una tendencia a un aumento moderado de las transaminasas con metotrexato (MTX). Conclusiones. La obesidad es un factor predictivo negativo de la respuesta clínica en pacientes con APs e iTNF-&amp;#945;. Exceptuando la hepatotoxicidad por el MTX, no se encontraron otros efectos adversos ni por otros fármacos en relación con la obesidad (AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);12(6): 307-312, nov.-dic. 2016. tab, graf</dc:source>
<dc:identifier>ibc-157430</dc:identifier>
<dc:title xml:lang="es">¿Se asocia la obesidad en la artritis psoriásica a una menor respuesta terapéutica y más efectos adversos con el tratamiento de fondo?</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d4869^s22038</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d8272^s22026</dc:subject>
<dc:subject>^d24542</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d12002^s22012</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:subject>^d4877^s22038</dc:subject>
<dc:subject>^d9951^s22012</dc:subject>
<dc:subject>^d50524^s22012</dc:subject>
<dc:subject>^d27938^s22073</dc:subject>
<dc:subject>^d28169^s22073</dc:subject>
<dc:subject>^d25783^s22045</dc:subject>
<dc:subject>^d1174^s22016</dc:subject>
<dc:subject>^d32355^s22000</dc:subject>
<dc:subject>^d1174^s22012</dc:subject>
<dc:subject>^d1174^s22067</dc:subject>
<dc:subject>^d32355^s22020</dc:subject>
<dc:subject>^d50524^s22016</dc:subject>
<dc:type>article</dc:type>
<dc:date>201612</dc:date>
</metadata>
</record>
</ibecs-document>
